Pre-dementia, most commonly called mild cognitive impairment (MCI), is a stage of cognitive decline that falls between normal aging and dementia. Roughly 1 in 5 people over age 50 have it. The defining feature: your thinking or memory is noticeably worse than expected for your age, but you can still handle daily life independently. That distinction from dementia, where cognitive problems start interfering with everyday tasks, is the key diagnostic boundary.
How MCI Differs From Normal Aging
Everyone’s brain slows down with age. Executive functions like planning, multitasking, and mental flexibility are typically the first to decline, and that’s normal. You might take longer to find a word or occasionally forget where you put your keys. This kind of slippage is subtle and doesn’t compromise your ability to live independently.
MCI is more pronounced than that. People with MCI show measurable impairment on cognitive tests, scoring meaningfully below what’s expected for their age and education level. The decline is often noticeable to family members or close friends, not just on formal testing. You might repeatedly forget important appointments, lose the thread of conversations more often, or struggle to follow the steps of familiar tasks like managing finances. But you can still cook, drive, dress yourself, and navigate your daily routine without help.
The Two Main Types
MCI comes in two broad forms, and the distinction matters because each points toward different possible futures.
Amnestic MCI primarily affects memory. People with this type have trouble learning and retaining new information, recalling recent events, or recognizing things they’ve encountered before. This form carries a higher risk of eventually progressing to Alzheimer’s disease.
Non-amnestic MCI affects cognitive skills other than memory. You might struggle with word-finding, visual-spatial tasks (like judging distances or navigating unfamiliar places), or planning and organizing. This type is more commonly associated with progression to other forms of dementia, such as Lewy body dementia. People with impairments in both memory and executive function face the highest risk of progressing to dementia compared to those with problems in just one area.
How Many People Progress to Dementia
Not everyone with MCI develops dementia. The progression rate depends heavily on the setting where the diagnosis is made. In specialty memory clinics, about 10% to 15% of people with MCI convert to dementia each year. In community-based studies, where people are screened regardless of whether they sought help, the annual rate drops to roughly 3% to 6%. The difference likely reflects that people who go to a clinic already have more noticeable symptoms.
Some people with MCI remain stable for years. Others actually improve, particularly when a treatable underlying cause is identified.
Conditions That Mimic Pre-Dementia
This is one of the most important things to know: several reversible conditions can produce cognitive symptoms that look exactly like MCI or early dementia. Depression is the most common. When severe, it can cause concentration problems, memory lapses, and slowed thinking that closely mimic neurodegeneration. Treating the depression often leads to partial or complete cognitive recovery.
Other reversible causes include vitamin B12 deficiency, hypothyroidism, medication side effects, sleep disorders, alcohol use disorder, and certain infections. Less commonly, conditions requiring surgical treatment, like normal pressure hydrocephalus (a buildup of fluid in the brain) or a chronic subdural hematoma (a slow bleed between the skull and brain), can cause progressive cognitive decline that reverses after treatment. This is why thorough medical evaluation matters. Cognitive decline that looks degenerative sometimes isn’t.
How Pre-Dementia Is Diagnosed
Diagnosis involves a combination of clinical interview, cognitive testing, and ruling out other causes. The formal criteria require four things: a cognitive complaint or noticeable decline, objective evidence of impairment on testing, essentially normal daily functioning, and the absence of dementia.
The Montreal Cognitive Assessment (MoCA) is one of the most widely used screening tools. It tests memory, attention, language, visual-spatial ability, and executive function in about 10 minutes. Scores of 25 or below (out of 30) generally suggest possible MCI in people aged 60 to 79, with slightly lower cutoffs for older age groups. A low score alone doesn’t confirm MCI, but it flags the need for further evaluation.
For people whose MCI may be an early stage of Alzheimer’s specifically, biomarker testing can provide additional clarity. Brain imaging can detect amyloid plaque buildup, and spinal fluid analysis can measure levels of amyloid and tau proteins. When both amyloid and tau markers are abnormal, the condition is classified as prodromal Alzheimer’s disease, meaning the biological process of Alzheimer’s has begun even though the person hasn’t reached the dementia stage. People with these biomarker profiles, particularly those with higher levels of tau (a marker of active nerve cell damage), are more likely to progress to dementia within two years.
Treatment Options
For years, there was no medication specifically approved for MCI. Cholinesterase inhibitors, the drugs commonly used for Alzheimer’s dementia, were studied extensively in MCI patients over trials lasting one to four years. None showed significant benefit, and none were approved for this stage.
That changed in 2023 and 2024 with the FDA approval of two anti-amyloid antibody treatments: lecanemab (approved 2023) and donanemab (approved 2024). Both are specifically indicated for early-stage Alzheimer’s, which includes people with MCI who have confirmed amyloid buildup in the brain. These drugs work by clearing amyloid plaques and have been shown to slow cognitive decline, though they don’t stop or reverse it. They require biomarker confirmation before prescribing, meaning you’d need a brain scan or spinal fluid test showing amyloid pathology to be eligible.
These treatments represent a shift in how the medical field approaches pre-dementia, but they’re relevant only to people whose MCI is driven by Alzheimer’s biology. For everyone else, management focuses on addressing reversible causes and lifestyle strategies.
What Actually Helps: Exercise and Cognitive Activity
The strongest non-drug evidence for slowing MCI progression comes from exercise, and the type of exercise matters. A large network meta-analysis comparing different exercise approaches found that multicomponent exercise (combining aerobic activity, strength training, and balance or flexibility work) was the most effective intervention for preserving overall cognitive function and executive skills in people with MCI. The effect size was substantial, nearly twice as large as any single exercise type alone.
Resistance training specifically stood out for memory. It was the only exercise type that showed significant benefits for memory function in MCI patients. Aerobic exercise alone, while beneficial for general brain health, didn’t produce the same targeted memory improvements.
The practical takeaway: a varied exercise routine that includes both strength training and aerobic activity offers the best cognitive protection. This isn’t a vague “stay active” recommendation. The research supports multicomponent exercise as a routine non-drug approach for people with MCI, with measurable effects on the cognitive domains most affected by the condition.
What Pre-Dementia Means for You
An MCI diagnosis is not a dementia diagnosis. It’s a signal that cognitive changes have crossed the threshold of normal aging, and it warrants attention, monitoring, and proactive steps. For some people, the cause is treatable and the decline is reversible. For others, it represents an early stage of a neurodegenerative process that may or may not progress. The annual risk of conversion to dementia in community settings is low enough that many people live with stable MCI for years.
What matters most at this stage is getting a thorough evaluation to rule out reversible causes, understanding whether biomarker testing is appropriate, and building the lifestyle habits, particularly regular multicomponent exercise, that have the strongest evidence for preserving cognitive function over time.